ArticleClinical and translational medicine2026

Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study.

Ying Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.